{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:52:43Z","timestamp":1769172763787,"version":"3.49.0"},"reference-count":48,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2020.4975","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T07:12:03Z","timestamp":1580800323000},"source":"Crossref","is-referenced-by-count":3,"title":["Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma"],"prefix":"10.3892","author":[{"given":"Yukari","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taketo","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Teshima","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motofumi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hosoi","sequence":"additional","affiliation":[{"name":"Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nagaoka","sequence":"additional","affiliation":[{"name":"Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Karasaki","sequence":"additional","affiliation":[{"name":"Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kakimi","sequence":"additional","affiliation":[{"name":"Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113\u20118655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"key20200713190321_b1-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"key20200713190321_b2-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"key20200713190321_b3-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: Renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"key20200713190321_b4-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/01.ju.0000165572.38887.da","article-title":"Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system","volume":"174","author":"Lam","year":"2005","journal-title":"J Urol"},{"key":"key20200713190321_b5-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","article-title":"Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review","volume":"34","author":"Gupta","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"key20200713190321_b6-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20200713190321_b7-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200713190321_b8-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200713190321_b9-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in renal cancer","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"key20200713190321_b10-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"key20200713190321_b11-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"key20200713190321_b12-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"key20200713190321_b13-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200713190321_b14-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713190321_b15-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20200713190321_b16-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713190321_b17-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"key20200713190321_b18-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"key20200713190321_b19-ijo-56-04-0999","first-page":"587","article-title":"NCCN guidelines updates: Management of metastatic kidney cancer","volume":"17","author":"Jonasch","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"key20200713190321_b20-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated european association of urology guidelines on renal cell carcinoma: Immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur Urol"},{"key":"key20200713190321_b21-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CCO.0000000000000466","article-title":"Immunotherapy-based combinations: An update","volume":"30","author":"Fuca","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"key20200713190321_b22-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nri.2016.70","article-title":"A guide to immunome-tabolism for immunologists","volume":"16","author":"O'Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"key20200713190321_b23-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"O'Donnell","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"key20200713190321_b24-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20200713190321_b25-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"key20200713190321_b26-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"key20200713190321_b27-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"key20200713190321_b28-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"key20200713190321_b29-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20200713190321_b30-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1158\/0008-5472.CAN-11-4094","article-title":"Cellular constituents of immune escape within the tumor microenvironment","volume":"72","author":"Kerkar","year":"2012","journal-title":"Cancer Res"},{"key":"key20200713190321_b31-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"key20200713190321_b32-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/leu.2008.58","article-title":"Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation","volume":"22","author":"Zhao","year":"2008","journal-title":"Leukemia"},{"key":"key20200713190321_b33-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2009.11.013","article-title":"Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice","volume":"135","author":"Gu","year":"2010","journal-title":"Clin Immunol"},{"key":"key20200713190321_b34-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20200713190321_b35-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","article-title":"Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained","volume":"70","author":"Ko","year":"2010","journal-title":"Cancer Res"},{"key":"key20200713190321_b36-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/CJI.0b013e3181f4c208","article-title":"A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients","volume":"33","author":"Adotevi","year":"2010","journal-title":"J Immunother"},{"key":"key20200713190321_b37-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/1471-2407-11-505","article-title":"Phase I-II study of everolimus and low-dose oral cyclophos-phamide in patients with metastatic renal cell cancer","volume":"11","author":"Huijts","year":"2011","journal-title":"BMC Cancer"},{"key":"key20200713190321_b38-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1158\/0008-5472.CAN-15-2452","article-title":"Rapalogs efficacy relies on the modulation of antitumor T-cell immunity","volume":"76","author":"Beziaud","year":"2016","journal-title":"Cancer Res"},{"key":"key20200713190321_b39-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0394632017734459","article-title":"Immunological effects of everolimus in patients with metastatic renal cell cancer","volume":"30","author":"Huijts","year":"2017","journal-title":"Int J Immunopathol Pharmacol"},{"key":"key20200713190321_b40-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","article-title":"Regulation of immune responses by mTOR","volume":"30","author":"Powell","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"key20200713190321_b41-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"key20200713190321_b42-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"key20200713190321_b43-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.immuni.2009.10.010","article-title":"The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin","volume":"32","author":"Rao","year":"2010","journal-title":"Immunity"},{"key":"key20200713190321_b44-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jim.2018.08.005","article-title":"Aging and the immune system: An overview","volume":"463","author":"Sadighi Akha","year":"2018","journal-title":"J Immunol Methods"},{"key":"key20200713190321_b45-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"268ra179","DOI":"10.1126\/scitranslmed.3009892","article-title":"mTOR inhibition improves immune function in the elderly","volume":"6","author":"Mannick","year":"2014","journal-title":"Sci Transl Med"},{"key":"key20200713190321_b46-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1002\/ijc.31842","article-title":"Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy","volume":"143","author":"Beziaud","year":"2018","journal-title":"Int J Cancer"},{"key":"key20200713190321_b47-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"207","DOI":"10.14712\/18059694.2017.84","article-title":"Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma","volume":"50","author":"Kopeck\u00fd","year":"2007","journal-title":"Acta Medica (Hradec Kralove)"},{"key":"key20200713190321_b48-ijo-56-04-0999","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s40425-019-0799-2","article-title":"Peripheral immune-based biomarkers in cancer immunotherapy: Can we realize their predictive potential?","volume":"7","author":"Nixon","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T19:07:59Z","timestamp":1594667279000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2020.4975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":48,"URL":"https:\/\/doi.org\/10.3892\/ijo.2020.4975","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]}}}